Loading clinical trials...

NasoNeb Delivery of an Intranasal Steroid | Clinical Trials | Clareo Health

COMPLETEDPHASE4

NasoNeb Delivery of an Intranasal Steroid

Evaluation of NasoNeb™ Delivery of an Intranasal Steroid in the Treatment of Perennial Allergic Rhinitis

NCT01270256•University of Chicago

Summary

The purpose of this study is to see if a nasal steroid drug delivered to the nose with the NasoNeb™ inhaler improves the symptoms of people with perennial allergic rhinitis (year round allergy symptoms).

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Males and females between 18 and 55 years of age.
•2. History of perennial allergic rhinitis.
•3. Positive skin test to dust mite, dog, cat or indoor mold antigen.
•4. And a combined nasal AM and PM score of ≥4 for nasal congestion in the day preceding entry and total nasal symptom score greater than 8.

Exclusion Criteria

•1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.
•2. Pregnant or lactating women.
•3. Subjects treated with systemic steroids during the previous 30 days.
•4. Subjects treated with topical (inhaled, intranasal or intraocular) steroids, Nasalcrom or Opticrom during the previous 30 days.
•5. Subjects treated with oral antihistamine/decongestants during the previous seven days.
•6. Subjects treated with topical (intranasal or intraocular) antihistamine/decongestants during the previous 3 days.
•7. Subjects treated with immunotherapy and are escalating their dose.
•8. Subjects on chronic anti-asthma medications.
•9. Subjects with polyps in the nose or a significantly displaced septum.
•10. Upper respiratory infection within 14 days prior to study start.

Locations (1)

University of Chicago

Chicago, Illinois, United States

Key Dates

Start Date

January 1, 2011

Primary Completion Date

July 1, 2012

Completion Date

August 1, 2012

Last Updated

July 25, 2014

Enrollment

ACTUAL participants

Conditions

Perennial Allergic Rhinitis

Interventions

Budesonide

DRUG

Placebo

DRUG

A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

NCT01425632

Perennial Allergic Rhinitis

View study

TERMINATEDPHASE3

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

NCT04874714

Allergic RhinoconjunctivitisPerennial Allergic Rhinitis+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 25, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

NasoNeb Delivery of an Intranasal Steroid

Inclusion Criteria

Exclusion Criteria

A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis

To Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients

A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)

Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis